Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly
MONDO:0017346A rare form of diffuse large B-cell lymphoma occurring most commonly in patients over the age of 50 (usually between 70-75 years of age), without overt immunodeficiency, and presenting with nodal and extranodal involvement (in sites such as the stomach, lung, skin and pancreas) and B symptoms (fever, night sweats, weight loss). The tumor is characterized by an aggressive course and a short survival rate.
Also known as: EBV Positive diffuse large B-cell lymphoma of the elderly, EBV-Positive diffuse large B-cell lymphoma, NOS, EBV-positive DLBCL of the elderly, Epstein-Barr Virus Positive diffuse large B-cell lymphoma of the elderly, Senile EBV-associated B-cell lymphoproliferative disorder, age-related EBV Positive B-cell lymphoproliferative disorder
2028 clinical trials for this condition and its sub-types, 23 tagged with Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
New hope for lymphoma: immune booster plus chemotherapy trial launches
Disease control Not yet recruitingThis Phase 2 trial tests whether adding epcoritamab, an immune-boosting drug, to standard R-CHOP chemotherapy can safely treat newly diagnosed aggressive B-cell lymphoma. About 20 adults with certain lymphoma types will receive the combination. The main goal is to check for a sid…
Phase 2 • Sponsor: Carrie Ho, MD • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Can a Four-Drug cocktail outsmart resistant lymphoma?
Disease control Not yet recruitingThis phase II trial is testing whether a combination of four drugs—sonrotoclax, glofitamab, gemcitabine, and oxaliplatin—can shrink or eliminate tumors in adults with large B-cell lymphoma that has returned or not responded to previous treatment. Participants will receive the dru…
Phase 2 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
New vaccine aims to fight Hard-to-Treat EBV cancers
Disease control Not yet recruitingThis study tests a vaccine called KSD-101 in 80 people with blood cancers linked to the Epstein-Barr virus (EBV). The vaccine uses a patient's own immune cells to target EBV and cancer. Researchers want to see if it can shrink tumors or keep the disease from coming back.
Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New hope for hard-to-treat lymphoma: three-drug combo enters early trials
Disease control Not yet recruitingThis early-phase trial tests whether combining three drugs (golcadomide, poseltinib, and rituximab) can shrink or control tumors in people with relapsed or refractory large B-cell lymphoma. About 20 adults will take part. The goal is to see if the combination works better than cu…
Phase 1/2 • Sponsor: Seoul National University Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New hope for rare lymphoma: drug combo targets tough cancer
Disease control Not yet recruitingThis study tests whether adding brentuximab vedotin to standard chemotherapy (R-CHP) works better for people newly diagnosed with a rare, aggressive lymphoma linked to the Epstein-Barr virus. About 25 adults will receive the combination and be followed for 2 years to see if the c…
Phase 2 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC